Distinguished in Neuroendocrine Tumor

Dr. Stephen Leong

Oncology
12605 E 16th Ave, 
Aurora, CO 
Distinguished in Neuroendocrine Tumor
12605 E 16th Ave, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Leong is an Oncologist in Aurora, Colorado. Dr. Leong is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Adrenocortical Carcinoma, Adrenal Cancer, Colorectal Cancer, and Familial Pancreatic Cancer.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 5 clinical trials in the study of Neuroendocrine Tumor.

Specialties
Oncology
Licenses
Internal Medicine in CO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

12605 E 16th Ave, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Methoxyamine, Pemetrexed Disodium
Study Phase: Phase 1/Phase 2
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: KPT-9274, Niacin ER, Nivolumab
Study Phase: Phase 1
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

41 Total Publications

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Journal: British journal of cancer
Published: January 25, 2023
Similar Doctors
Distinguished in Neuroendocrine Tumor
Dr. Christopher H. Lieu
Oncology
Distinguished in Neuroendocrine Tumor
Dr. Christopher H. Lieu
Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.4 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Lieu is an Oncologist in Aurora, Colorado. Dr. Lieu is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, Pancreatic Cancer, and Tissue Biopsy. Dr. Lieu is currently accepting new patients.

Distinguished in Neuroendocrine Tumor
Dr. Marc S. Schwartz
Hematology Oncology | Oncology | Hematology
Distinguished in Neuroendocrine Tumor
Dr. Marc S. Schwartz
Hematology Oncology | Oncology | Hematology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
 (0.1 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Schwartz is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Schwartz is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neurofibromatosis Type 2 (NF2), Acute Lymphoblastic Leukemia (ALL), Neuroendocrine Tumor, Bone Marrow Aspiration, and Colonoscopy. Dr. Schwartz is currently accepting new patients.

Distinguished in Neuroendocrine Tumor
Dr. Alexis D. Leal
Oncology
Distinguished in Neuroendocrine Tumor
Dr. Alexis D. Leal
Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.4 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexis Leal is an Oncologist in Aurora, Colorado. Dr. Leal is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), and Tissue Biopsy. Dr. Leal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leong's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile